PHIA Koninklijke Philips N.V.

Philips launches HealthSuite Clinical Trial Accelerator to help life science organizations run more flexible, patient-centric clinical trials

Philips launches HealthSuite Clinical Trial Accelerator to help life science organizations run more flexible, patient-centric clinical trials

May 19, 2020

Amsterdam, the Netherlands – (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced Clinical Trial Accelerator on Philips HealthSuite. This new tailored set of capabilities allows life science organizations to integrate, analyze and store clinical and patient-reported data from multiple sources, providing actionable insights for better, faster decision-making.

Philips HealthSuite is an integrated, modular set of standards-based capabilities that support the development of digital propositions across the health continuum, encompassing HIPAA compliant, secure cloud capabilities. Clinical Trial Accelerator enables patient-centric trials at home, managing the collection of data while providing the security and compliance expected from both patients and life science organizations.

Life science organizations face continued pressure to run more efficient, cost-effective clinical trials. Empowering patients and making it easier for them to stay connected and contribute to a trial can have a significant impact on compliance rates and overall success. At the same time, collecting data and identifying actionable insights while ensuring the security and compliance of patient information is key. Clinical Trial Accelerator is designed to address these challenges, helping life science organizations reach their goals faster and supporting greater flexibility in trial design.

“Philips HealthSuite already provides cloud-based services and tools to a wide array of healthcare organizations, and with Clinical Trial Accelerator we have created a tailored set of capabilities to support life science organizations,” said Dale Wiggins, General Manager for the HealthSuite digital platform at Philips. “Our innovative, flexible cloud platform leverages our global healthcare capabilities and is supported by our compliance, security and interoperability expertise.”

Tailored capabilities to accelerate clinical trials

Other HealthSuite capabilities include an AI Analytics Workbench for enhanced decision making and standards-based interoperability for Digital Imaging and Communication in Medicine (DICOM) data, as well as the HealthSuite Clinical Data Lake, a new scalable micro-service that acts as a centralized big data repository for high-volume clinical data collection studies and includes controls to curate and manage data in a manner that addresses regulatory requirements.

These capabilities offer companies cloud-based services and technical tools that meet privacy, security and regulatory requirements that they can use to develop and run a new generation of connected healthcare applications. Unlike other digital platforms, HealthSuite is purpose-built to solve the complex challenges of healthcare, featuring capabilities to manage device data, collect personal and health data, store and share data securely, analyze data, build and deploy AI models, and create solutions on the cloud.

In addition, these HealthSuite capabilities power a wide range of both Philips and 3rd party connected healthcare applications in areas including image-guided therapy, sleep and respiratory care, ophthalmology, telehealth and self-medication. For 3rd party collaborations, Philips is the provider of the relevant cloud-based healthcare IT infrastructure and is not involved in the commercialization of the products and services of these companies. More information on Philips HealthSuite can be found at .

For further information, please contact:

Mark Groves

Philips Global Press Office

Tel:

Email:

Twitter:

About Royal Philips

Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company focused on improving people's health and enabling better outcomes across the health continuum from healthy living and prevention, to diagnosis, treatment and home care. Philips leverages advanced technology and deep clinical and consumer insights to deliver integrated solutions. Headquartered in the Netherlands, the company is a leader in diagnostic imaging, image-guided therapy, patient monitoring and health informatics, as well as in consumer health and home care. Philips generated 2019 sales of EUR 19.5 billion and employs approximately 81,000 employees with sales and services in more than 100 countries. News about Philips can be found at .

Attachments

EN
19/05/2020

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Koninklijke Philips N.V.

 PRESS RELEASE

Philips publishes its Annual Report 2025

Philips publishes its Annual Report 2025 February 19, 2026 Amsterdam, the Netherlands – (NYSE: PHG, AEX: PHIA), a global leader in health technology, today published its Annual Report 2025. Philips’ Annual Report 2025 will be on the agenda of the Annual General Meeting of Shareholders (AGM), to be held on May 8, 2026. The convocation notice and the agenda, including explanatory notes, for the AGM will be published in due course. Philips filed the Annual Report 2025 with the Netherlands Authority for the Financial Markets (AFM) in European Single Electronic Format (ESEF) and expects to f...

 PRESS RELEASE

Philips introduces InkSpace Imaging’s Snuggle™ flexible pediatric MRI ...

Philips introduces InkSpace Imaging’s Snuggle™ flexible pediatric MRI coil for its 3.0T MR systems, helping to enhance imaging precision, efficiency and comfort February 12, 2026 Amsterdam, the Netherlands – (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced the availability of the InkSpace Imaging Snuggle™ pediatric body array coil for Philips 3.0T MRI systems. Designed specifically for pediatric patients, the Snuggle coil has been optimized and validated for use with Philips 3.0T MRI systems, bringing enhanced comfort for children and efficient, high-quality i...

ING Helpdesk
  • ING Helpdesk

Benelux Morning Notes

ABN Amro: Miss but strong capital, good set of results / Ahold Delhaize: Strong 4Q25 but no major surprise on FY26 adj. EPS guidance / Alfen: No recovery yet and another transitional year / BAM Group: Preview: 2026 outlook the key item / Econocom: Better REBITA, net debt, but EBIT below, much lower net profit, dividend halved, 2026-28 guidance postponed to “medium term” / Exor: Ferrari 4Q25 and 2026 guidance beat / Gecina: Results and guidance in line, DPS set to grow over 2026-30 / Heineken: No...

Oscar Rodriguez
  • Oscar Rodriguez

PHILIPS: RDOS. 4T’25 Y CAMBIO DE P.O. AL ALZA (ANÁLISIS BANCO SABADELL...

Rdos. 4T’25 vs 4T’24: Ventas: 5.097 M euros (+1,1% vs -0,9% BS(e) y -1,0% consenso); EBITA Aj.: 770 M euros (+13,4% vs +0,6% BS(e) y -1,0% consenso); BDI: 397 M euros (-333 M euros en 2024 vs 275 M euros BS(e) y 276 M euros consenso); Rdos. 2025 vs 2024: Ventas: 17.834 M euros (-1,0% vs -1,6% BS(e) y -1,6% consenso); EBITA Aj.: 2.195 M euros (+5,7% vs +1,5% BS(e) y +1,0% consenso); BDI: 897 M euros (-698 M euros en 2024 vs 775 M euros BS(e) y 776 M euros consenso).

ResearchPool Subscriptions

Get the most out of your insights

Get in touch